Post-earnings recap
Reported
Thu, May 1, 2025
EPS actual
$-0.01
EPS est.
$-1.00
EPS surprise
+99.00%
1-day move
-3.08%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Alnylam Pharmaceuticals reported a narrower-than-expected loss per share, which was a positive surprise for investors. However, the stock fell by 3.08% in reaction, likely due to the absence of revenue figures and future guidance. Investors may be concerned about the lack of clarity on the company's financial outlook.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | +99.00% |
| Revenue | N/A | N/A | N/A |
Management remains cautiously optimistic about the future, focusing on pipeline advancements. However, they did not provide specific guidance for the upcoming quarters.
Management highlighted the progress in their pipeline despite the lack of revenue guidance.
They expressed confidence in upcoming product launches and their potential impact.